PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy

被引:32
|
作者
Markowski, Mark C. [1 ]
Chen, Yongmei [2 ]
Feng, Zhaoyong [3 ]
Cullen, Jennifer [2 ]
Trock, Bruce J. [3 ]
Suzman, Daniel [1 ]
Antonarakis, Emmanuel S. [1 ]
Paller, Channing J. [1 ]
Rosner, Inger [2 ]
Han, Misop [3 ]
Walsh, Patrick C. [3 ]
Partin, Alan W. [3 ]
Eisenberger, Mario [1 ]
机构
[1] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Dept Oncol, Baltimore, MD USA
[2] Uniformed Serv Univ Hlth Sci, Dept Surg, Ctr Prostate Dis Res, Bethesda, MD 20814 USA
[3] Johns Hopkins Univ, Dept Urol, Brady Urol Inst, Baltimore, MD USA
基金
美国国家卫生研究院;
关键词
Biochemical recurrence; Deferred ADT; Natural history; Post-prostatectomy; PSA cut-point; SALVAGE RADIOTHERAPY; RADIATION-THERAPY; NATURAL-HISTORY; ANTIGEN; PROGRESSION; MORTALITY; DISEASE; POINT;
D O I
10.1016/j.clgc.2019.08.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In men with biochemically-recurrent prostate cancer, prostate-specific antigen doubling time <= 7.5 months, prostate-specific antigen >= 0.5 ng/mL, and Gleason score are independent predictors of metastasis-free survival on multivariable analysis. These data can assist physicians during discussions with patients regarding the risk of developing metastatic disease and for clinical trial planning. Introduction: The aim of this study was to investigate the association of prostate-specific antigen (PSA) values on metastasis-free survival (MFS) in men with biochemically recurrent prostate cancer (BRPC) and PSA doubling time (PSADT) < 12 months. This dataset also reflects an update with longer follow-up of our prior publications on the natural history of BRPC in the absence of treatment. Materials and Methods: In this report, we combined databases from the Center for Prostate Disease Research and Johns Hopkins University (CPDR/JHU). In the CPDR/JHU radical prostatectomy database (30,936 total patients), 656 men with BRPC (> 0.2 ng/mL) after prostatectomy and PSADT < 12 months, who received no adjuvant/salvage androgen deprivation and/or radiation therapy, were prospectively followed until radiologic evidence of metastasis and are included in this analysis. Results: Metastasis occurred in 250 of 656 patients with BRPC (median follow-up, 5 years). PSADT < 7.5 months and Gleason score were independent risk factors for distant metastasis in multivariable analysis. Risk of metastasis increased for PSADT 6.01 to 7.50, 4.51 to 6.0, 3.01 to 4.50, and <= 3.0 months, after adjusting for Gleason score. A PSA value >= 0.5 ng/mL significantly and independently increased risk of metastasis in patients with PSADT < 12 months (hazard ratio, 2.79; 95% confidence interval, 1.47-5.29; P = .001). Conclusions: In men with PSADT < 12 months, PSADT <= 7.5 months, PSA >= 0.5 ng/mL, and Gleason score are independent predictors of MFS on multivariable analysis. (C) 2019 Elsevier Inc. All rights reserved.
引用
收藏
页码:470 / +
页数:7
相关论文
共 50 条
  • [1] PSA doubling time (PSADT) and proximal PSA value predict metastasis-free survival (MFS) in men with biochemically recurrent prostate cancer (BRPC) after radical prostatectomy (RP).
    Markowski, Mark Christopher
    Suzman, Daniel
    Chen, Yongmei
    Trock, Bruce J.
    Cullen, Jennifer
    Feng, Zhaoyong
    Antonarakis, Emmanuel S.
    Paller, Channing Judith
    Han, Misop
    Partin, Alan W.
    Eisenberger, Mario A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] PSA doubling time (PSADT) and proximal PSA predict metastasis-free survival (MFS) in men with biochemically recurrent prostate cancer (BRPC) after radical prostatectomy (RP): Implications for patient counseling and clinical trial design
    Markowski, M.
    Chen, Y.
    Feng, Z.
    Trock, B.
    Cullen, J.
    Suzman, D.
    Antonarakis, E.
    Paller, C.
    Han, M.
    Partin, A.
    Eisenberger, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [3] Changes in PSA kinetics predict metastasis-free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents
    Antonarakis, Emmanuel S.
    Zahurak, Marianna L.
    Lin, Jianqing
    Keizman, Daniel
    Carducci, Michael A.
    Eisenberger, Mario A.
    CANCER, 2012, 118 (06) : 1533 - 1542
  • [4] The effect of the frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer
    Paller, C. J.
    Olatoye, D.
    Xie, S.
    Zhou, X.
    Denmeade, S. R.
    Eisenberger, M. A.
    Antonarakis, E. S.
    Carducci, M. A.
    Rosner, G. L.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2014, 17 (01) : 28 - 33
  • [5] The effect of the frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer
    C J Paller
    D Olatoye
    S Xie
    X Zhou
    S R Denmeade
    M A Eisenberger
    E S Antonarakis
    M A Carducci
    G L Rosner
    Prostate Cancer and Prostatic Diseases, 2014, 17 : 28 - 33
  • [6] The effect of PSA frequency and duration on PSA doubling time (PSADT) calculations in men with biochemically recurrent prostate cancer (BRPC) after definitive local therapy.
    Paller, Channing Judith
    Xie, Sherlly
    Olatoye, Dare
    Denmeade, Samuel R.
    Eisenberger, Mario A.
    Antonarakis, Emmanuel S.
    Carducci, Michael Anthony
    Rosner, Gary L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] PSA doubling time (PSADT) ≤6 months to identify a subgroup of men with biochemically-recurrent prostate cancer (BRPC) after prostatectomy (RP) at highest risk of distant metastasis (dMET).
    Suzman, Daniel L.
    Cullen, Jennifer
    Trock, Bruce J.
    Chen, Yongmei
    Rosner, Inger L.
    Feng, Zhaoyong
    Antonarakis, Emmanuel S.
    Han, Misop
    Partin, Alan W.
    Hurwitz, Lauren
    Kuo, Huai-Ching
    McLeod, David G.
    Eisenberger, Mario A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy
    Schweizer, M. T.
    Zhou, X. C.
    Wang, H.
    Yang, T.
    Shaukat, F.
    Partin, A. W.
    Eisenberger, M. A.
    Antonarakis, E. S.
    ANNALS OF ONCOLOGY, 2013, 24 (11) : 2881 - 2886
  • [9] Role of 18F-Choline PET/CT in Biochemically Relapsed Prostate Cancer After Radical Prostatectomy Correlation With Trigger PSA, PSA Velocity, PSA Doubling Time, and Metastatic Distribution
    Marzola, Maria Cristina
    Chondrogiannis, Sotirios
    Ferretti, Alice
    Grassetto, Gaia
    Rampin, Lucia
    Massaro, Arianna
    Castellucci, Paolo
    Picchio, Maria
    Al-Nahhas, Adil
    Colletti, Patrick M.
    Marcolongo, Adriano
    Rubello, Domenico
    CLINICAL NUCLEAR MEDICINE, 2013, 38 (01) : E26 - E32
  • [10] Public health impact of PSA doubling time after radical prostatectomy on prostate cancer specific and overall survival.
    Freedland, S. J.
    Humphreys, E. B.
    Mangold, L. A.
    Eisenberger, M.
    George, D. J.
    Partin, A. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 233S - 233S